2. Metabolic Enzyme/Protease Anti-infection
  3. Endogenous Metabolite Bacterial
  4. Erucamide

Erucamide  (Synonyms: cis-13-Docosenamide)

Cat. No.: HY-W009123 Purity: 99.32%
COA
SDS
Handling Instructions Technical Support

Erucamide is an orally active, blood-brain barrier-permeable TMEM19 ligand and T3SS inhibitor. Erucamide exerts retinal neuroprotective effects in mouse models of retinal degeneration. Erucamide attenuates depression- and anxiety-like behaviors in mice.\n\nErucamide binds to the conserved hydrophobic pocket in HrcC, disrupts its outer membrane localization, and blocks T3SS-mediated effector protein secretion in Gram-negative pathogenic bacteria. Erucamide enhances the antimicrobial immunity of plants against pathogenic bacteria. Erucamide can be used in research related to retinitis pigmentosa, anxiety and depression, bacterial wilt, and bacterial blight.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Erucamide

Erucamide 화학구조

CAS No. : 112-84-5

사이즈 가격 재고 수량
Solution
10 mM * 1 mL in Ethanol 해외재고보유
Solid
1 g 해외재고보유
5 g 해외재고보유
10 g   견적 받기  
50 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 Customer Validation

Other Forms of Erucamide:

Erucamide Related Antibodies

Top Publications Citing Use of Products

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Erucamide is an orally active, blood-brain barrier-permeable TMEM19 ligand and T3SS inhibitor. Erucamide exerts retinal neuroprotective effects in mouse models of retinal degeneration. Erucamide attenuates depression- and anxiety-like behaviors in mice.\n\nErucamide binds to the conserved hydrophobic pocket in HrcC, disrupts its outer membrane localization, and blocks T3SS-mediated effector protein secretion in Gram-negative pathogenic bacteria. Erucamide enhances the antimicrobial immunity of plants against pathogenic bacteria. Erucamide can be used in research related to retinitis pigmentosa, anxiety and depression, bacterial wilt, and bacterial blight[1][2][3][4].

In Vitro

Erucamide (0.64 μM) significantly upregulates the expressions of PDGFα, CTGF, PDGFβ, CX3CL1, Ang1 and BDNF in CD11b+ MPCs, and this effect depends on the transmembrane protein TMEM19[1].
Erucamide specifically binds to the transmembrane protein TMEM19 in HMC3 microglial cells and TMEM19-overexpressing HEK293T cells[1].
Erucamide (6-150 μM, 20 h) inhibits T3SS-mediated secretion of AvrPto in P. syringae pv. tomato DC3000[2].
Erucamide (150 μM, 20 h) inhibits the secretion and assembly of the P. syringae T3SS, as well as Hrp pilus assembly, by binding to HrcC and preventing the outer membrane localization of HrcC and HrpA[2].
Erucamide (6-150 μM) dose-dependently inhibits the growth of P. syringae in Arabidopsis thaliana, while it restores antimicrobial immune activity in erucamide-accumulation-deficient plant lines[2].
Erucamide reduces the severity of bacterial diseases and the proliferation level of pathogens in rice and *Nicotiana benthamiana*, as well as the bacterial wilt severity and mortality rate of tomato plants[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Erucamide Related Antibodies

Western Blot Analysis[2]

Cell Line: P. syringae pv. tomato DC3000
Concentration: 6, 30, 150 μM
Incubation Time: 20 h
Result: Inhibited AvrPto secretion, with 150 μM erucamide reducing secretion by 83%.

Western Blot Analysis[2]

Cell Line: P. syringae
Concentration: 150 μM
Incubation Time: 20 h
Result: Altered the thermal stability of HrcC, causing a shift in the unfolding transition (Tm).
In Vivo

Erucamide (214 ng; subretinal injection; administered on postnatal days 12 and 22) significantly reduces photoreceptor atrophy, increases retinal layer thickness, preserves deep retinal vascular structures, and improves rod-mediated visual function in RD10 mice at P32[1].
Erucamide (214 ng; intravitreal injection; single administration) activates CD116+ myeloid cells in the retina of wild-type mice, thereby increasing the expression levels of proangiogenic factors and neurotrophic factors[1].
Erucamide (5-20 mg/kg, p.o., 7 days) attenuates depression- and anxiety-like behaviors in mice, and its antidepressant and anxiolytic effects may be associated with the regulation of the hypothalamic-pituitary-adrenal (HPA) axis[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: RD10 (B6.CXB1-Pde6brd10/J) mice (postnatal day 12, 22, and 32)[1]
Dosage: 214 ng
Administration: subretinal; at postnatal day 12 and 22
Result: Increased surviving photoreceptor rows to 6.4 at P32.
Significantly increased outer nuclear layer thickness. Significantly increased inner nuclear layer thickness. Significantly protected intraretinal deep plexus vasculature from vaso-obliteration.
Significantly increased scotopic B-wave amplitude at 50 cd*s/m2 intensity.
Animal Model: Wild-type mice[1]
Dosage: 214 ng
Administration: intravitreal; single injection
Result: Induced widespread infiltration of GS-Lectin-positive CD116⁺ myeloid cells throughout the retina.
Upregulated expression of pro-angiogenic and neurotrophic genes including PDGF, CTGF, CX3CL1, Ang1, and BDNF in flow cytometry-sorted CD116⁺ cells from treated retinas.
Animal Model: Male adult Kunming mice (18-22 g)[4]
Dosage: 5, 10, 20 mg/kg
Administration: p.o., 7 days
Result: Reduced the resting time in mice during TST and FST tests.
Increased the open-arm and open-arm injection times in the elevation plus maze test.
Decreased serum ACTH, CORT, and T-AOC levels.
분자량

337.58

화학식

C22H43NO
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCC/C=C\CCCCCCCCCCCC(N)=O
선적

Room temperature in continental US; may vary elsewhere.
보관
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
용액&용해도
In Vitro: 

Ethanol : 12.5 mg/mL (37.03 mM; Need ultrasonic)

DMSO : 1.56 mg/mL (4.62 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9623 mL 14.8113 mL 29.6226 mL
5 mM 0.5925 mL 2.9623 mL 5.9245 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% EtOH    90% Corn Oil

    Solubility: ≥ 1.25 mg/mL (3.70 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서

Purity: 99.32%

SDS (396 KB)

COA (237 KB) HNMR (254 KB) RP-HPLC (236 KB) MS (84 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / Ethanol 1 mM 2.9623 mL 14.8113 mL 29.6226 mL 74.0565 mL
Ethanol 5 mM 0.5925 mL 2.9623 mL 5.9245 mL 14.8113 mL
10 mM 0.2962 mL 1.4811 mL 2.9623 mL 7.4057 mL
15 mM 0.1975 mL 0.9874 mL 1.9748 mL 4.9371 mL
20 mM 0.1481 mL 0.7406 mL 1.4811 mL 3.7028 mL
25 mM 0.1185 mL 0.5925 mL 1.1849 mL 2.9623 mL
30 mM 0.0987 mL 0.4937 mL 0.9874 mL 2.4686 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Erucamide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Erucamide112-84-5cis-13-DocosenamideEndogenous MetaboliteBacterialTMEM19 LigandT3SS InhibitorHMC3 microglial cellsHEK293T cellsCD11b+ MPCsRD10 miceretinitis pigmentosaanxiety and depressionbacterial wiltbacterial blight
Inhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Erucamide
Cat. No.:
HY-W009123
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.